Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Lanman RB"'
Autor:
Ikeda, S, Tsigelny, IF, Skjevik, AA, Kono, Y, Mendler, M, Kuo, A, Sicklick, JK, Heestand, G, Banks, KC, Talasaz, A, Lanman, RB, Lippman, S, Kurzrock, R
Publikováno v:
The oncologist, vol 23, iss 5
Ikeda, S; Tsigelny, IF; Skjevik, AA; Kono, Y; Mendler, M; Kuo, A; et al.(2018). Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. ONCOLOGIST, 23(5), 586-593. doi: 10.1634/theoncologist.2017-0479. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1kw8n456
Ikeda, S; Tsigelny, IF; Skjevik, AA; Kono, Y; Mendler, M; Kuo, A; et al.(2018). Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. ONCOLOGIST, 23(5), 586-593. doi: 10.1634/theoncologist.2017-0479. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1kw8n456
BACKGROUND:Because imaging has a high sensitivity to diagnose hepatocellular carcinoma (HCC) and tissue biopsies carry risks such as bleeding, the latter are often not performed in HCC. Blood-derived circulating tumor DNA (ctDNA) analysis can identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0d38f2c37e433fd9f96bc0669d00a8be
https://escholarship.org/uc/item/1kw8n456
https://escholarship.org/uc/item/1kw8n456
Autor:
Carneiro, BA, Collier, KA, Nagy, RJ, Pamarthy, S, Sagar, V, Fairclough, S, Odegaard, J, Lanman, RB, Costa, R, Taxter, T, Kuzel, TM, Fan, A, Chae, YK, Cristofanilli, M, Hussain, MH, Abdulkadir, SA, Giles, FJ
PARP1/2 inhibitors are effective against BRCA2-deficient tumors. The PARP inhibitor (PARPi) olaparib received FDA breakthrough designation for treatment of metastatic castration-resistant prostate cancers (CRPC) carrying mutations in BRCA1/2 or ATM g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmc_________::0362328964ff9825aae15e061b49137c
https://europepmc.org/articles/PMC6732782/
https://europepmc.org/articles/PMC6732782/
Autor:
Collisson, Eric, Lanman, RB, Mortimer, SA, Zill, OA, Sebisanovic, D, Lopez, R, Blau, S, Collisson, EA, Divers, SG, Hoon, DSB, Scott, E
Publikováno v:
Collisson, Eric; Lanman, RB; Mortimer, SA; Zill, OA; Sebisanovic, D; Lopez, R; et al.(2015). Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/2967n1gx
© 2015 Lanman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::52553b1ae3fbbe590e51b4efec292f76
http://www.escholarship.org/uc/item/2967n1gx
http://www.escholarship.org/uc/item/2967n1gx
Autor:
Lanman RB (AUTHOR)
Publikováno v:
New England Journal of Medicine. 7/22/93, Vol. 329 Issue 4, p277-278. 2p.
Autor:
Valerie M. Jansen, Yao Lu, Paula Gonzalez Ericsson, Wei He, Luis J. Schwarz, Richard B. Lanman, Dhivya R. Sudhan, Yu Shyr, Teresa C. Dugger, Yan Guo, Carlos L. Arteaga, Marcelo Rocha Cruz, Alberto Servetto, Ingrid A. Mayer, Amir Behdad, Aditya Bardia, Luigi Formisano, Sarah Croessmann, Nadia Solovieff, Angel Guerrero-Zotano, Fei Su, Michelle Miller, Justin M. Balko, Mellissa J. Nixon, Joyce O'Shaughnessy, Ariella B. Hanker, Kyungmin Lee, Melinda E. Sanders, Massimo Cristofanilli, Joshua A. Bauer, Rebecca J. Nagy
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Nature Communications
Nature Communications
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867afa6a277eebe06a4fa212f3467c8a
https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
Autor:
Alexander EK (AUTHOR), Kennedy GC (AUTHOR), Baloch ZW (AUTHOR), Cibas ES (AUTHOR), Chudova D (AUTHOR), Diggans J (AUTHOR), Friedman L (AUTHOR), Kloos RT (AUTHOR), LiVolsi VA (AUTHOR), Mandel SJ (AUTHOR), Raab SS (AUTHOR), Rosai J (AUTHOR), Steward DL (AUTHOR), Walsh PS (AUTHOR), Wilde JI (AUTHOR), Zeiger MA (AUTHOR), Lanman RB (AUTHOR), Haugen BR (AUTHOR)
Publikováno v:
New England Journal of Medicine. 8/23/2012, Vol. 367 Issue 8, p705-715. 11p.
Autor:
Alshad S. Lalani, Rebecca J. Nagy, Richard E. Cutler, Eric H. Bernicker, Carlos L. Arteaga, Nick V. Grishin, Aju Mathew, Sarah Croessmann, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Massimo Cristofanilli, Luigi Formisano, Jie He, Vincent A. Miller, Richard B. Lanman, Dhivya R. Sudhan
Purpose: We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. Experimental Design: ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85a503b2ade4c0662de8574ca2fd605f
https://europepmc.org/articles/PMC6320312/
https://europepmc.org/articles/PMC6320312/
Autor:
Lanman RB; Institute for Historical Ecology, Los Altos, California, United States of America., Batter TJ; Elk and Pronghorn Program, Big Game Unit, Wildlife Branch, California Department of Fish and Wildlife, West Sacramento, California, United States of America., Mckee CJ; Elk and Moose Program, Game Division, Nevada Department of Wildlife, Reno, Nevada, United States of America.
Publikováno v:
PloS one [PLoS One] 2024 Sep 18; Vol. 19 (9), pp. e0301665. Date of Electronic Publication: 2024 Sep 18 (Print Publication: 2024).
Autor:
Ezeife DA; Department of Oncology, Tom Baker Cancer Center, 1331 29 St NW, Toronto, ON T2N 4N2, Canada University of Calgary, Calgary, AB, Canada., Spackman E; University of Calgary, Calgary, AB, Canada., Juergens RA; Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada., Laskin JJ; BC Cancer, The University of British Columbia, Vancouver, BC, Canada., Agulnik JS; Jewish General Hospital, McGill University, Montreal, QC, Canada., Hao D; Tom Baker Cancer Center, Calgary, AB, Canada University of Calgary, Calgary AB, Canada., Laurie SA; Ottawa Hospital Research Institute/Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Law JH; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Le LW; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Kiedrowski LA; Guardant Health, Inc., Redwood City, CA, Canada., Melosky B; BC Cancer, The University of British Columbia, Vancouver, BC, Canada., Shepherd FA; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Cohen V; Jewish General Hospital, McGill University, Montreal, QC, Canada., Wheatley-Price P; Ottawa Hospital Research Institute/Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Vandermeer R; Niagara Health, St. Catharines, ON, Canada., Li JJ; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Fernandes R; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Shokoohi A; BC Cancer, The University of British Columbia, Vancouver, BC, Canada., Lanman RB; Guardant Health, Inc., Redwood City, CA, Canada., Leighl NB; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Publikováno v:
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2022 Jul 26; Vol. 14, pp. 17588359221112696. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).
Autor:
Lapin M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Chagani S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raina A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Madwani K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Holley VR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Lanman RB; Guardant Health, Redwood City, CA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raymond VM; Guardant Health, Redwood City, CA., Kwong LN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100197.